Compare Abbott Laboratories (ABT) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Salesforce Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Salesforce Inc trades at $165.8 (market cap $138.84B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CRM | |
|---|---|---|
Market Cap | $166.94B | $138.84B |
Sector | Health | Technology |
52-Week High | $136.62 | $273.65 |
52-Week Low | $82.57 | $150.12 |
Enterprise Value | $193.69B | $168.88B |
Dividend Yield | 2.63% | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Salesforce (CRM) trades at $166.38, showing modest daily gains of 0.44% amid a challenging year-to-date decline of approximately 35%. The stock exhibits a mixed technical picture with bullish overall signals but bearish moving averages, while fundamentally, the company demonstrates strong profitability with a 77.64% gross margin and consistent earnings beats. Recent news highlights significant AI momentum with Agentforce and Data 360 ARR reaching $2.9 billion, though software sector sentiment remains pressured by AI disruption concerns.
The investment outlook balances robust fundamentals against near-term headwinds. Strong revenue growth to $37.9 billion, expanding net income margins to 18.73%, and a discounted valuation with a P/E of 19.64 present opportunity. However, risks include intense AI competition, sector-wide software sell-offs, and technical resistance near $170. Analyst consensus remains bullish with a $235.20 price target, suggesting significant upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
